-
1
-
-
79960205374
-
European Society of Cardiology (ESC); European Atherosclerosis Society (EAS)
-
ESC/EAS Guidelines for the management of dyslipidaemias, ** Current ESC/EAS guidelines for the management of dyslipidaemia
-
Catapano AL, Reiner Z, De Backer G, et al.; European Society of Cardiology (ESC); European Atherosclerosis Society (EAS). ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011; 217: 3-46. ** Current ESC/EAS guidelines for the management of dyslipidaemia
-
(2011)
Atherosclerosis
, vol.217
, pp. 3-46
-
-
Catapano, A.L.1
Reiner, Z.2
De Backer, G.3
-
2
-
-
84897970506
-
American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
-
** Current ACC/AHA guidelines for the management of dyslipidaemia
-
Stone NJ, Robinson JG, Lichtenstein AH, et al.; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129: S1-45. ** Current ACC/AHA guidelines for the management of dyslipidaemia
-
(2014)
Circulation
, vol.129
, pp. 1-45
-
-
Stone, N.J.1
Robinson, J.G.2
Lichtenstein, A.H.3
-
3
-
-
84872712625
-
2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult
-
** Current guidelines of the Canadian Cardiovascular Society for the management of dyslipidaemia
-
Anderson TJ, Grégoire J, Hegele RA, et al. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol 2013; 29: 151-67. ** Current guidelines of the Canadian Cardiovascular Society for the management of dyslipidaemia
-
(2013)
Can J Cardiol
, vol.29
, pp. 151-167
-
-
Anderson, T.J.1
Grégoire, J.2
Hegele, R.A.3
-
6
-
-
84883337835
-
Statins for primary prevention of cardiovascular disease: The benefits outweigh the risks
-
Minder CM, Blumenthal RS, Blaha MJ. Statins for primary prevention of cardiovascular disease: the benefits outweigh the risks. Curr Opin Cardiol 2013; 28: 554-60.
-
(2013)
Curr Opin Cardiol
, vol.28
, pp. 554-560
-
-
Minder, C.M.1
Blumenthal, R.S.2
Blaha, M.J.3
-
7
-
-
84883182510
-
Statins for primary prevention: Problems with cardiovascular-risk estimation?
-
Reiner Z. Statins for primary prevention: problems with cardiovascular-risk estimation? Nat Rev Cardiol 2013; 10: 547.
-
(2013)
Nat Rev Cardiol
, vol.10
, pp. 547
-
-
Reiner, Z.1
-
8
-
-
84891764226
-
Reassessing the benefits of statins in the prevention of cardiovascular disease in diabetic patients—a systematic review and meta-analysis
-
Chang YH, Hsieh MC, Wang CY, et al. Reassessing the benefits of statins in the prevention of cardiovascular disease in diabetic patients—a systematic review and meta-analysis. Rev Diabet Stud 2013; 10: 157-70.
-
(2013)
Rev Diabet Stud
, vol.10
, pp. 157-170
-
-
Chang, Y.H.1
Hsieh, M.C.2
Wang, C.Y.3
-
10
-
-
84930860402
-
Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update
-
Athyros VG, Tziomalos K, Katsiki N, et al. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update. World J Gastroenterol 2015; 21: 6820-34.
-
(2015)
World J Gastroenterol
, vol.21
, pp. 6820-6834
-
-
Athyros, V.G.1
Tziomalos, K.2
Katsiki, N.3
-
11
-
-
84933523805
-
Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction?
-
Athyros VG, Katsiki N, Karagiannis A, Mikhailidis DP. Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction? Expert Opin Pharmacother 2015; 16: 1449-61.
-
(2015)
Expert Opin Pharmacother
, vol.16
, pp. 1449-1461
-
-
Athyros, V.G.1
Katsiki, N.2
Karagiannis, A.3
Mikhailidis, D.P.4
-
13
-
-
84892384634
-
Effect of statins on cardiovascular events in patients with mild to moderate chronic kidney disease: A systematic review and meta-analysis of randomized clinical trials
-
Zhang X, Xiang C, Zhou YH, et al. Effect of statins on cardiovascular events in patients with mild to moderate chronic kidney disease: a systematic review and meta-analysis of randomized clinical trials. BMC CardiovascDisord 2014; 14: 19.
-
(2014)
BMC Cardiovascdisord
, vol.14
, pp. 19
-
-
Zhang, X.1
Xiang, C.2
Zhou, Y.H.3
-
14
-
-
84942772639
-
HMG CoA reductase inhibitors (Statins) for people with chronic kidney disease not requiring dialysis
-
Palmer SC, Navaneethan SD, Craig JC, et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev 2014; 5: CD007784.
-
(2014)
Cochrane Database Syst Rev
, vol.5
-
-
Palmer, S.C.1
Navaneethan, S.D.2
Craig, J.C.3
-
16
-
-
84933526603
-
Do statins reduce the cardiovascular risk in patients with rheumatoid arthritis?
-
Danninger K, Hoppe UC, Pieringer H. Do statins reduce the cardiovascular risk in patients with rheumatoid arthritis? Int J Rheum Dis 2014; 17: 606-11.
-
(2014)
Int J Rheum Dis
, vol.17
, pp. 606-611
-
-
Danninger, K.1
Hoppe, U.C.2
Pieringer, H.3
-
17
-
-
84881329514
-
Statin therapy and new-onset diabetes: Molecular mechanisms and clinical relevance
-
Banach M, Malodobra-Mazur M, Gluba A, et al. Statin therapy and new-onset diabetes: molecular mechanisms and clinical relevance. Curr Pharm Des 2013; 19: 4904-12.
-
(2013)
Curr Pharm Des
, vol.19
, pp. 4904-4912
-
-
Banach, M.1
Malodobra-Mazur, M.2
Gluba, A.3
-
18
-
-
84865147415
-
Pharmacotherapy: Statins and newonset diabetesmellitus--a matter for debate
-
Athyros VG, Mikhailidis DP. Pharmacotherapy: statins and newonset diabetesmellitus--a matter for debate. Nat Rev Endocrinol 2012; 8: 133-4.
-
(2012)
Nat Rev Endocrinol
, vol.8
, pp. 133-134
-
-
Athyros, V.G.1
Mikhailidis, D.P.2
-
19
-
-
84923653355
-
New-onset diabetes and statins: Throw the bath water out, but, please, keep the baby!
-
* A recent comment on statin-related NOD
-
Katsiki N, Rizzo M, Mikhailidis DP, Mantzoros CS. New-onset diabetes and statins: throw the bath water out, but, please, keep the baby! Metabolism 2015; 64: 471-5. * A recent comment on statin-related NOD
-
(2015)
Metabolism
, vol.64
, pp. 471-475
-
-
Katsiki, N.1
Rizzo, M.2
Mikhailidis, D.P.3
Mantzoros, C.S.4
-
20
-
-
84964691274
-
Statin tolerability: In defence of placebocontrolled trials
-
Aug 28. pii: 2047487315602861. [Epub ahead of print]
-
Tobert JA, Newman CB. Statin tolerability: In defence of placebocontrolled trials. Eur J PrevCardiol 2015 Aug 28. pii: 2047487315602861. [Epub ahead of print]
-
(2015)
Eur J Prevcardiol
-
-
Tobert, J.A.1
Newman, C.B.2
-
21
-
-
84921513738
-
Statin treatment non-adherence and discontinuation: Clinical implications and potential solutions
-
Phan K, Gomez YH, Elbaz L, Daskalopoulou SS. Statin treatment non-adherence and discontinuation: clinical implications and potential solutions. Curr PharmDes 2014; 20: 6314-24.
-
(2014)
Curr Pharmdes
, vol.20
, pp. 6314-6324
-
-
Phan, K.1
Gomez, Y.H.2
Elbaz, L.3
Daskalopoulou, S.S.4
-
22
-
-
84899883299
-
The National Lipid AssociationStatin Intolerance Panel. An assessment by the Statin Intolerance Panel: 2014update
-
Guyton JR, Bays HE, Grundy SM, Jacobson TA. The National Lipid AssociationStatin Intolerance Panel. An assessment by the Statin Intolerance Panel: 2014update. J ClinLipidol 2014; 8: S72-81.
-
(2014)
J Clinlipidol
, vol.8
, pp. S72-S81
-
-
Guyton, J.R.1
Bays, H.E.2
Grundy, S.M.3
Jacobson, T.A.4
-
23
-
-
84899893293
-
The National Lipid Association's Muscle Safety Expert Panel. An assessment by the Statin Muscle Safety Task Force: 2014 update
-
** Current guidelines for statin intolerance
-
Rosenson RS, Baker SK, Jacobson TA, et al. The National Lipid Association's Muscle Safety Expert Panel. An assessment by the Statin Muscle Safety Task Force: 2014 update. J ClinLipidol 2014; 8: S58-71. ** Current guidelines for statin intolerance
-
(2014)
J Clinlipidol
, vol.8
, pp. S58-S71
-
-
Rosenson, R.S.1
Baker, S.K.2
Jacobson, T.A.3
-
24
-
-
84888237339
-
Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update
-
Mancini GB, Tashakkor AY, Baker S, et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update. Can J Cardiol 2013; 29: 1553-68.
-
(2013)
Can J Cardiol
, vol.29
, pp. 1553-1568
-
-
Mancini, G.B.1
Tashakkor, A.Y.2
Baker, S.3
-
25
-
-
84927742065
-
European Atherosclerosis Society Consensus Panel. Statin-associated muscle symptoms: Impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management
-
Current guidelines for statin intolerance
-
Stroes ES, Thompson PD, Corsini A, et al.; European Atherosclerosis Society Consensus Panel. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J 2015; 36: 1012-22. Current guidelines for statin intolerance
-
(2015)
Eur Heart J
, vol.36
, pp. 1012-1022
-
-
Stroes, E.S.1
Thompson, P.D.2
Corsini, A.3
-
26
-
-
84924981752
-
Statin intolerance-an attempt at a unified definition. Position paper from an International Lipid Expert Panel
-
** Current guidelines for statin intolerance
-
Banach M, Rizzo M, Toth PP, et al. Statin intolerance-an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci 2015; 11: 1-23. ** Current guidelines for statin intolerance
-
(2015)
Arch Med Sci
, vol.11
, pp. 1-23
-
-
Banach, M.1
Rizzo, M.2
Toth, P.P.3
-
27
-
-
84925847173
-
Adverse effects of statins-myths and reality
-
Simic I, Reiner Z. Adverse effects of statins-myths and reality. Curr Pharm Des 2015; 21: 1220-6.
-
(2015)
Curr Pharm Des
, vol.21
, pp. 1220-1226
-
-
Simic, I.1
Reiner, Z.2
-
28
-
-
84994009625
-
Statin Useand the Risk of Kidney Disease With Long-Term Follow-Up (8.4-Year Study)
-
Dec 2. [Epub ahead of print]
-
Acharya T, Huang J, Tringali S, Frei CR, Mortensen EM, Mansi IA. Statin Useand the Risk of Kidney Disease With Long-Term Follow-Up (8.4-Year Study). Am J Cardiol 2015 Dec 2. [Epub ahead of print]
-
(2015)
Am J Cardiol
-
-
Acharya, T.1
Huang, J.2
Tringali, S.3
Frei, C.R.4
Mortensen, E.M.5
Mansi, I.A.6
-
29
-
-
84937734258
-
Preoperative Statin Therapy and RenalOutcomes After Cardiac Surgery: A Meta-analysis and Metaregression of 59, 771 Patients
-
Wang J, Gu C, Gao M, et al. Preoperative Statin Therapy and RenalOutcomes After Cardiac Surgery: A Meta-analysis and Metaregression of 59, 771 Patients. Can J Cardiol 2015; 31: 1051-60.
-
(2015)
Can J Cardiol
, vol.31
, pp. 1051-1060
-
-
Wang, J.1
Gu, C.2
Gao, M.3
-
30
-
-
84908066776
-
Meta-analysis on efficacy of statins for prevention of contrast-induced acute kidney injury in patients undergoing coronary angiography
-
Ukaigwe A, Karmacharya P, Mahmood M, et al. Meta-analysis on efficacy of statins for prevention of contrast-induced acute kidney injury in patients undergoing coronary angiography. Am J Cardiol 2014; 114: 1295-302.
-
(2014)
Am J Cardiol
, vol.114
, pp. 1295-1302
-
-
Ukaigwe, A.1
Karmacharya, P.2
Mahmood, M.3
-
31
-
-
84923384596
-
Short-, mid-, and long-term benefits of peri-procedural high-intensity statin administration in patients undergoing percutaneous coronary intervention
-
Athyros VG, Katsiki N, Karagiannis A, Mikhailidis DP. Short-, mid-, and long-term benefits of peri-procedural high-intensity statin administration in patients undergoing percutaneous coronary intervention. Curr Med Res Opin 2015; 31: 191-5.
-
(2015)
Curr Med Res Opin
, vol.31
, pp. 191-195
-
-
Athyros, V.G.1
Katsiki, N.2
Karagiannis, A.3
Mikhailidis, D.P.4
-
33
-
-
84900337040
-
Treatment and impact ofdyslipidemia in diabetic nephropathy
-
Toyama T, Shimizu M, Furuichi K, et al. Treatment and impact ofdyslipidemia in diabetic nephropathy. ClinExpNephrol 2014; 18: 201-5.
-
(2014)
Clinexpnephrol
, vol.18
, pp. 201-205
-
-
Toyama, T.1
Shimizu, M.2
Furuichi, K.3
-
34
-
-
79960430739
-
Assessing The Treatment Effect in Metabolic syndrome without Perceptible diabeTes (ATTEMPT) Collaborative Group. Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study
-
Athyros VG, Karagiannis A, Ganotakis ES, et al.; Assessing The Treatment Effect in Metabolic syndrome without Perceptible diabeTes (ATTEMPT) Collaborative Group. Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study. Curr Med Res Opin 2011; 27: 1659-68.
-
(2011)
Curr Med Res Opin
, vol.27
, pp. 1659-1668
-
-
Athyros, V.G.1
Karagiannis, A.2
Ganotakis, E.S.3
-
35
-
-
33846023704
-
Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: A subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study
-
Athyros VG, Mikhailidis DP, Liberopoulos EN, et al. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant 2007; 22: 118-27.
-
(2007)
Nephrol Dial Transplant
, vol.22
, pp. 118-127
-
-
Athyros, V.G.1
Mikhailidis, D.P.2
Liberopoulos, E.N.3
-
36
-
-
84897018134
-
Statins in chronic kidney disease: Cardiovascular risk and kidney function
-
Deedwania PC. Statins in chronic kidney disease: cardiovascular risk and kidney function. Postgrad Med 2014; 126: 29-36.
-
(2014)
Postgrad Med
, vol.126
, pp. 29-36
-
-
Deedwania, P.C.1
-
37
-
-
41549159287
-
TNT (Treating to New Targets) Investigators. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: The TNT (Treating to New Targets) study
-
Shepherd J, Kastelein JJ, Bittner V, et al.; TNT (Treating to New Targets) Investigators. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J AmCollCardiol 2008; 51: 1448-54.
-
(2008)
J Amcollcardiol
, vol.51
, pp. 1448-1454
-
-
Shepherd, J.1
Kastelein, J.J.2
Bittner, V.3
-
38
-
-
84883771761
-
Statins are associated with reduced risk of gastric cancer: A systematic review and meta-analysis
-
Singh PP, Singh S. Statins are associated with reduced risk of gastric cancer: a systematic review and meta-analysis. Ann Oncol 2013; 24: 1721-30.
-
(2013)
Ann Oncol
, vol.24
, pp. 1721-1730
-
-
Singh, P.P.1
Singh, S.2
-
39
-
-
84881491358
-
Statins are associated with a reduced risk of hepatocellular cancer: A systematic review and meta-analysis
-
Singh S, Singh PP, Singh AG, et al. Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology 2013; 144: 323-32.
-
(2013)
Gastroenterology
, vol.144
, pp. 323-332
-
-
Singh, S.1
Singh, P.P.2
Singh, A.G.3
-
40
-
-
84941253605
-
Prognostic Significance of Statin Use in Colorectal Cancer: A Systematic Review andMeta-Analysis
-
Ling Y, Yang L, Huang H, et al. Prognostic Significance of Statin Use in Colorectal Cancer: A Systematic Review andMeta-Analysis. Medicine (Baltimore) 2015; 94: e908.
-
(2015)
Medicine (Baltimore)
, vol.94
-
-
Ling, Y.1
Yang, L.2
Huang, H.3
-
41
-
-
84862492891
-
Statin use and risk of pancreatic cancer: A meta-analysis
-
Cui X, Xie Y, Chen M, et al. Statin use and risk of pancreatic cancer: a meta-analysis. Cancer Causes Control2012; 23: 1099-111.
-
Cancer Causes Control2012
, vol.23
, pp. 1099-1111
-
-
Cui, X.1
Xie, Y.2
Chen, M.3
-
42
-
-
84874545071
-
Statins and the risk of lung cancer: A meta-analysis
-
Tan M, Song X, Zhang G, et al. Statins and the risk of lung cancer: a meta-analysis. PLoS One 2013; 8: e57349.
-
(2013)
Plos One
, vol.8
-
-
Tan, M.1
Song, X.2
Zhang, G.3
-
43
-
-
84865144986
-
Statin use and risk of breast cancer: A meta-analysis of observational studies
-
Undela K, Srikanth V, Bansal D. Statin use and risk of breast cancer: a meta-analysis of observational studies. Breast Cancer Res Treat 2012; 135: 261-9.
-
(2012)
Breast Cancer Res Treat
, vol.135
, pp. 261-269
-
-
Undela, K.1
Srikanth, V.2
Bansal, D.3
-
44
-
-
84876472135
-
Statin use and risk of bladder cancer: A meta-analysis
-
Zhang XL, Geng J, Zhang XP, et al. Statin use and risk of bladder cancer: a meta-analysis. Cancer Causes Control 2013; 24: 769-76.
-
(2013)
Cancer Causes Control
, vol.24
, pp. 769-776
-
-
Zhang, X.L.1
Geng, J.2
Zhang, X.P.3
-
45
-
-
84894471681
-
Statin use and risk of kidney cancer: A meta-analysis of observational studies and randomized trials
-
Zhang XL, Liu M, Qian J, et al. Statin use and risk of kidney cancer: a meta-analysis of observational studies and randomized trials. Br J ClinPharmacol 2014; 77: 458-65.
-
(2014)
Br J Clinpharmacol
, vol.77
, pp. 458-465
-
-
Zhang, X.L.1
Liu, M.2
Qian, J.3
-
46
-
-
84876826457
-
Association between statin usage and prostate cancer prevention: A refined meta-analysis based on literature from the years 2005-2010
-
Zhang Y, Zang T. Association between statin usage and prostate cancer prevention: a refined meta-analysis based on literature from the years 2005-2010. Urol Int 2013; 90: 259-62.
-
(2013)
Urol Int
, vol.90
, pp. 259-262
-
-
Zhang, Y.1
Zang, T.2
-
47
-
-
84921669806
-
Statins are potential anti cancerous agents (Review)
-
Altwairgi AK. Statins are potential anti cancerous agents (review). Oncol Rep 2015; 33: 1019-39.
-
(2015)
Oncol Rep
, vol.33
, pp. 1019-1039
-
-
Altwairgi, A.K.1
-
48
-
-
84896824167
-
Neuropsychiatric adverse eventsassociated with statins: Epidemiology, pathophysiology, prevention andmanagement
-
Tuccori M, Montagnani S, Mantarro S, et al. Neuropsychiatric adverse eventsassociated with statins: epidemiology, pathophysiology, prevention andmanagement. CNS Drugs 2014; 28: 249-72.
-
(2014)
CNS Drugs
, vol.28
, pp. 249-272
-
-
Tuccori, M.1
Montagnani, S.2
Mantarro, S.3
-
49
-
-
84908356833
-
Regarding long-term statin therapy: Are we trading stronger hearts for weaker brains?
-
Goldstein MR, Mascitelli L. Regarding long-term statin therapy: are we trading stronger hearts for weaker brains? Med Hypotheses 2014; 83: 346-51.
-
(2014)
Med Hypotheses
, vol.83
, pp. 346-351
-
-
Goldstein, M.R.1
Mascitelli, L.2
-
50
-
-
84903301576
-
Statins in nervous systemassociated diseases: Angels or devils?
-
Lei Q, Peng WN, You H, Hu ZP, Lu W. Statins in nervous systemassociated diseases: angels or devils? Pharmazie 2014; 69: 448-54.
-
(2014)
Pharmazie
, vol.69
, pp. 448-454
-
-
Lei, Q.1
Peng, W.N.2
You, H.3
Hu, Z.P.4
Lu, W.5
-
52
-
-
84901501976
-
Cognitive effects of statin medications
-
Kelley BJ, Glasser S. Cognitive effects of statin medications. CNS Drugs 2014; 28: 411-9.
-
(2014)
CNS Drugs
, vol.28
, pp. 411-419
-
-
Kelley, B.J.1
Glasser, S.2
-
53
-
-
84888265005
-
Statins and cognitive function: A systematic review
-
Richardson K, Schoen M, French B, et al. Statins and cognitive function: a systematic review. Ann Intern Med 2013; 159: 688-97.
-
(2013)
Ann Intern Med
, vol.159
, pp. 688-697
-
-
Richardson, K.1
Schoen, M.2
French, B.3
-
54
-
-
84888861145
-
Statins and cognition: A systematic review and meta-analysis of short-and long-term cognitive effects
-
Swiger KJ, Manalac RJ, Blumenthal RS, et al. Statins and cognition: a systematic review and meta-analysis of short-and long-term cognitive effects. Mayo Clin Proc 2013; 88: 1213-21.
-
(2013)
Mayo Clin Proc
, vol.88
, pp. 1213-1221
-
-
Swiger, K.J.1
Manalac, R.J.2
Blumenthal, R.S.3
-
55
-
-
84885918484
-
Association of statin use with risk of dementia: A meta-analysis of prospective cohort studies
-
Song Y, Nie H, Xu Y, et al. Association of statin use with risk of dementia: a meta-analysis of prospective cohort studies. Geriatr-GerontolInt 2013; 13: 817-24.
-
(2013)
Geriatr-Gerontolint
, vol.13
, pp. 817-824
-
-
Song, Y.1
Nie, H.2
Xu, Y.3
-
56
-
-
84875805775
-
Statins in the prevention of dementia and Alzheimer's disease: A meta-analysis of observational studies and an assessment of confounding
-
Wong WB, Lin VW, Boudreau D, Devine EB. Statins in the prevention of dementia and Alzheimer's disease: a meta-analysis of observational studies and an assessment of confounding. Pharmacoepidemiol Drug Saf 2013; 22: 345-58.
-
(2013)
Pharmacoepidemiol Drug Saf
, vol.22
, pp. 345-358
-
-
Wong, W.B.1
Lin, V.W.2
Boudreau, D.3
Devine, E.B.4
-
57
-
-
65049089153
-
Statins: Mechanisms of neuroprotection
-
van der Most PJ, Dolga AM, Nijholt IM, Luiten PG, Eisel UL. Statins: mechanisms of neuroprotection. ProgNeurobiol 2009; 88: 64-75.
-
(2009)
Progneurobiol
, vol.88
, pp. 64-75
-
-
Van Der Most, P.J.1
Dolga, A.M.2
Nijholt, I.M.3
Luiten, P.G.4
Eisel, U.L.5
-
58
-
-
78649890465
-
GREACE Study Collaborative Group. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: A post-hoc analysis
-
Athyros VG, Tziomalos K, Gossios TD, et al.; GREACE Study Collaborative Group. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010; 376: 1916-22.
-
(2010)
Lancet
, vol.376
, pp. 1916-1922
-
-
Athyros, V.G.1
Tziomalos, K.2
Gossios, T.D.3
-
59
-
-
84936806639
-
Resolution of nonalcoholic steatohepatitis by rosuvastatin mono therapy in patients with metabolic syndrome
-
Kargiotis K, Athyros VG, Giouleme O, et al. Resolution of nonalcoholic steatohepatitis by rosuvastatin mono therapy in patients with metabolic syndrome. World J Gastroenterol 2015; 21: 7860-8.
-
(2015)
World J Gastroenterol
, vol.21
, pp. 7860-7868
-
-
Kargiotis, K.1
Athyros, V.G.2
Giouleme, O.3
-
60
-
-
84930482185
-
Statins and liver disease: From concern to 'wonder' drugs?
-
Bosch J, Forns X. Therapy. Statins and liver disease: from concern to 'wonder' drugs? Nat Rev GastroenterolHepatol 2015; 12: 320-1.
-
(2015)
Nat Rev Gastroenterolhepatol
, vol.12
, pp. 320-321
-
-
Bosch, J.1
Therapy, F.X.2
-
61
-
-
84939268765
-
Statin use and nonalcoholic steatohepatitis in at risk individuals
-
* A recent study reporting statin-related benefits on liver dysfunction
-
Dongiovanni P, Petta S, Mannisto V, et al. Statin use and nonalcoholic steatohepatitis in at risk individuals. J Hepatol 2015; 63: 705-12. * A recent study reporting statin-related benefits on liver dysfunction
-
(2015)
J Hepatol
, vol.63
, pp. 705-712
-
-
Dongiovanni, P.1
Petta, S.2
Mannisto, V.3
-
62
-
-
34249342305
-
Statins in nonalcoholic fatty liver disease and chronically elevated liver enzymes: A histopathological follow-up study
-
Ekstedt M, Franzén LE, Mathiesen UL, et al. Statins in nonalcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. J Hepatol 2007; 47: 135-41.
-
(2007)
J Hepatol
, vol.47
, pp. 135-141
-
-
Ekstedt, M.1
Franzén, L.E.2
Mathiesen, U.L.3
-
63
-
-
84894257853
-
Clinical approaches to non-alcoholic fatty liver disease
-
Schwenger KJ, Allard JP. Clinical approaches to non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20: 1712-23.
-
(2014)
World J Gastroenterol
, vol.20
, pp. 1712-1723
-
-
Schwenger, K.J.1
Allard, J.P.2
-
64
-
-
84886254094
-
IDEAL Investigators. Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-tomoderate baseline elevations in alanine aminotransferase levels
-
Tikkanen MJ, Fayyad R, Faergeman O, et al.; IDEAL Investigators. Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-tomoderate baseline elevations in alanine aminotransferase levels. Int J Cardiol 2013; 168: 3846-52.
-
(2013)
Int J Cardiol
, vol.168
, pp. 3846-3852
-
-
Tikkanen, M.J.1
Fayyad, R.2
Faergeman, O.3
-
65
-
-
84899810207
-
The National Lipid Association's Statin Safety Task Force. An assessment by the Statin Liver Safety Task Force: 2014 update
-
Bays H, Cohen DE, Chalasani N, Harrison SA, The National Lipid Association's Statin Safety Task Force. An assessment by the Statin Liver Safety Task Force: 2014 update. J ClinLipidol 2014; 8: S47-57.
-
(2014)
J Clinlipidol
, vol.8
, pp. S47-S57
-
-
Bays, H.1
Cohen, D.E.2
Chalasani, N.3
Harrison, S.A.4
-
66
-
-
84861543083
-
The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, Ameri can College of Gastroenterology, and the American Gastroenterological Association
-
Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, Ameri can College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005-23.
-
(2012)
Hepatology
, vol.55
, pp. 2005-2023
-
-
Chalasani, N.1
Younossi, Z.2
Lavine, J.E.3
-
67
-
-
84875850647
-
Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus
-
Navarese EP, Buffon A, Andreotti F, et al. Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. Am J Cardiol 2013; 111: 1123-30.
-
(2013)
Am J Cardiol
, vol.111
, pp. 1123-1130
-
-
Navarese, E.P.1
Buffon, A.2
Andreotti, F.3
-
68
-
-
79959428660
-
Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: A meta-analysis
-
Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 2011; 305: 2556-64.
-
(2011)
JAMA
, vol.305
, pp. 2556-2564
-
-
Preiss, D.1
Seshasai, S.R.2
Welsh, P.3
-
69
-
-
84921493092
-
Kuchenbaecker KB, et al.HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: Evidence from genetic analysis and randomised trials
-
Swerdlow DI, Preiss D, Kuchenbaecker KB, et al.HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet 2015; 385 (9965): 351-61.
-
(2015)
Lancet
, vol.385
, Issue.9965
, pp. 351-361
-
-
Swerdlow, D.I.1
Preiss, D.2
-
70
-
-
77549087054
-
Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials
-
Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010; 375: 735-42.
-
(2010)
Lancet
, vol.375
, pp. 735-742
-
-
Sattar, N.1
Preiss, D.2
Murray, H.M.3
-
71
-
-
84864861863
-
Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: An analysis from the JUPITER trial
-
Ridker PM, Pradhan A, MacFadyen JG, et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 2012; 380: 565-71.
-
(2012)
Lancet
, vol.380
, pp. 565-571
-
-
Ridker, P.M.1
Pradhan, A.2
Macfadyen, J.G.3
-
72
-
-
84866733914
-
Statins, risk of diabetes, and implications on outcomes in the general population
-
Wang KL, Liu CJ, Chao TF, et al. Statins, risk of diabetes, and implications on outcomes in the general population. J Am CollCardiol 2012; 60: 1231-8.
-
(2012)
J am Collcardiol
, vol.60
, pp. 1231-1238
-
-
Wang, K.L.1
Liu, C.J.2
Chao, T.F.3
-
73
-
-
84897031074
-
Cardiovascular drugs that increase the risk of new onset diabetes
-
Ong KL, Barter PJ, Waters DD. Cardiovascular drugs that increase the risk of new onset diabetes. Am Heart J 2014; 167: 421-8.
-
(2014)
Am Heart J
, vol.167
, pp. 421-428
-
-
Ong, K.L.1
Barter, P.J.2
Waters, D.D.3
-
74
-
-
84861869259
-
Assessing the Treatment Effect in Metabolic Syndrome Without Perceptible Diabetes (ATTEMPT) Collaborative Group. Long-term impact of multifactorial treatment on new-onset diabetes and related cardiovascular events in metabolic syndrome: A post hoc ATTEMPT analysis
-
Athyros VG, Elisaf MS, Alexandrides T, et al.; Assessing the Treatment Effect in Metabolic Syndrome Without Perceptible Diabetes (ATTEMPT) Collaborative Group. Long-term impact of multifactorial treatment on new-onset diabetes and related cardiovascular events in metabolic syndrome: a post hoc ATTEMPT analysis. Angiology 2012; 63: 358-66.
-
(2012)
Angiology
, vol.63
, pp. 358-366
-
-
Athyros, V.G.1
Elisaf, M.S.2
Alexandrides, T.3
-
75
-
-
85027957106
-
Lipid-lowering therapies, glucose control and incident diabetes: Evidence, mechanisms and clinical implications
-
Zafrir B, Jain M. Lipid-lowering therapies, glucose control and incident diabetes: evidence, mechanisms and clinical implications. Cardiovasc Drugs Ther 2014; 28: 361-77.
-
(2014)
Cardiovasc Drugs Ther
, vol.28
, pp. 361-377
-
-
Zafrir, B.1
Jain, M.2
-
76
-
-
84936817948
-
Effect of pitavastatin on glucose, HbA1c and incident diabetes: A metaanalysis of randomized controlled clinical trials in individuals without diabetes
-
Vallejo-Vaz AJ, KondapallySeshasai SR, Kurogi K, et al. Effect of pitavastatin on glucose, HbA1c and incident diabetes: A metaanalysis of randomized controlled clinical trials in individuals without diabetes. Atherosclerosis 2015; 241: 409-18.
-
(2015)
Atherosclerosis
, vol.241
, pp. 409-418
-
-
Vallejo-Vaz, A.J.1
Kondapallyseshasai, S.R.2
Kurogi, K.3
-
77
-
-
84899092930
-
Effect of high-dose pitavastatin on glucose homeostasis in patients at elevated risk of new-onset diabetes: Insights from the CAPITAIN and PREVAILUS studies
-
Chapman MJ, Orsoni A, Robillard P, et al. Effect of high-dose pitavastatin on glucose homeostasis in patients at elevated risk of new-onset diabetes: insights from the CAPITAIN and PREVAILUS studies. Curr Med Res Opin 2014; 30: 775-84.
-
(2014)
Curr Med Res Opin
, vol.30
, pp. 775-784
-
-
Chapman, M.J.1
Orsoni, A.2
Robillard, P.3
-
79
-
-
84875200123
-
Intermittent nondaily dosing strategies inpatients with previous statin-induced myopathy
-
Keating AJ, Campbell KB, Guyton JR. Intermittent nondaily dosing strategies inpatients with previous statin-induced myopathy. Ann Pharmacother 2013; 47: 398-404.
-
(2013)
Ann Pharmacother
, vol.47
, pp. 398-404
-
-
Keating, A.J.1
Campbell, K.B.2
Guyton, J.R.3
-
81
-
-
82955203309
-
Impact of 10 mg rosuvastatin daily or alternate-day on lipid profile and inflammatory markers
-
Li JJ, Yang P, Liu J, et al. Impact of 10 mg rosuvastatin daily or alternate-day on lipid profile and inflammatory markers. ClinChimActa 2012; 413: 139-42.
-
(2012)
Clinchimacta
, vol.413
, pp. 139-142
-
-
Li, J.J.1
Yang, P.2
Liu, J.3
-
82
-
-
59549099998
-
The comparison of the effects of standard 20 mg atorvastatin daily and 20 mg atorvastatin every other day on serum LDL-cholesterol and highsensitive Creactive protein levels
-
Kele_ T, AkarBayram N, Kayhan T, et al. The comparison of the effects of standard 20 mg atorvastatin daily and 20 mg atorvastatin every other day on serum LDL-cholesterol and highsensitive Creactive protein levels. AnadoluKardiyolDerg 2008; 8: 407-12.
-
(2008)
Anadolukardiyolderg
, vol.8
, pp. 407-412
-
-
Kele, T.1
Akarbayram, N.2
Kayhan, T.3
-
83
-
-
0036708211
-
Daily dosing versus alternate-day dosing of simvastatinin patients with hypercholesterolemia
-
Copher HR, Stewart RD. Daily dosing versus alternate-day dosing of simvastatinin patients with hypercholesterolemia. Pharmacotherapy 2002; 22: 1110-6.
-
(2002)
Pharmacotherapy
, vol.22
, pp. 1110-1116
-
-
Copher, H.R.1
Stewart, R.D.2
-
84
-
-
79960831385
-
Efficacy and tolerability of once-weekly rosuvastatin in patients with previous statin intolerance
-
Kennedy SP, Barnas GP, Schmidt MJ, et al. Efficacy and tolerability of once-weekly rosuvastatin in patients with previous statin intolerance. J ClinLipidol 2011; 5: 308-15.
-
(2011)
J Clinlipidol
, vol.5
, pp. 308-315
-
-
Kennedy, S.P.1
Barnas, G.P.2
Schmidt, M.J.3
-
85
-
-
84858222560
-
Daily and intermittent rosuvastatin 5_mg therapy in statin intolerant patients: An observational study
-
Meek C, Wierzbicki AS, Jewkes C, et al. Daily and intermittent rosuvastatin 5_mg therapy in statin intolerant patients: an observational study. Curr Med Res Opin 2012; 28: 371-8.
-
(2012)
Curr Med Res Opin
, vol.28
, pp. 371-378
-
-
Meek, C.1
Wierzbicki, A.S.2
Jewkes, C.3
-
86
-
-
84903170344
-
American College of Cardiology/ American Heart Association Task Force on Practice Guidelines. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines
-
Eckel RH, Jakicic JM, Ard JD, et al.; American College of Cardiology/ American Heart Association Task Force on Practice Guidelines. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines. J Am CollCardiol 2014; 63: 2960-84.
-
(2014)
J am Collcardiol
, vol.63
, pp. 2960-2984
-
-
Eckel, R.H.1
Jakicic, J.M.2
Ard, J.D.3
-
87
-
-
84949191337
-
The Interaction between Statins and Exercise: Mechanisms and Strategies to Counter the Musculoskeletal Side Effects of This Combination Therapy
-
Deichmann RE, Lavie CJ, Asher T, DiNicolantonio JJ, O'Keefe JH, Thompson PD. The Interaction between Statins and Exercise: Mechanisms and Strategies to Counter the Musculoskeletal Side Effects of This Combination Therapy. Ochsner J 2015; 15: 429-37.
-
(2015)
Ochsner J
, vol.15
, pp. 429-437
-
-
Deichmann, R.E.1
Lavie, C.J.2
Asher, T.3
Dinicolantonio, J.J.4
O'keefe, J.H.5
Thompson, P.D.6
-
88
-
-
84916238750
-
Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. Analysis of vitamin D levels in patients with and without statinassociatedmyalgia-a systematic review and meta-analysis of 7 studies with 2420 patients
-
Michalska-Kasiczak M, Sahebkar A, Mikhailidis DP, et al; Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. Analysis of vitamin D levels in patients with and without statinassociatedmyalgia-a systematic review and meta-analysis of 7 studies with 2420 patients. Int J Cardiol 2015; 178: 111-6.
-
(2015)
Int J Cardiol
, vol.178
, pp. 111-116
-
-
Michalska-Kasiczak, M.1
Sahebkar, A.2
Mikhailidis, D.P.3
-
89
-
-
84912083886
-
Vitamin D status modifies the association between statin use and musculoskeletal pain: A population based study
-
Morioka TY, Lee AJ, Bertisch S, Buettner C. Vitamin D status modifies the association between statin use and musculoskeletal pain: a population based study. Atherosclerosis 2015; 238: 77-82.
-
(2015)
Atherosclerosis
, vol.238
, pp. 77-82
-
-
Morioka, T.Y.1
Lee, A.J.2
Bertisch, S.3
Buettner, C.4
-
90
-
-
84925445316
-
StatinIntolerance Because of Myalgia, Myositis, Myopathy, or Myonecrosis Can in MostCases be Safely Resolved by Vitamin D Supplementation
-
Khayznikov M, Hemachrandra K, Pandit R, et al. StatinIntolerance Because of Myalgia, Myositis, Myopathy, or Myonecrosis Can in MostCases be Safely Resolved by Vitamin D Supplementation. N Am J Med Sci 2015; 7: 86-93.
-
(2015)
N am J Med Sci
, vol.7
, pp. 86-93
-
-
Khayznikov, M.1
Hemachrandra, K.2
Pandit, R.3
-
91
-
-
84929358911
-
Links between Vitamin D Deficiency and Cardiovascular Diseases
-
Mozos I, Marginean O. Links between Vitamin D Deficiency and Cardiovascular Diseases. BiomedRes Int 2015; 2015: 109275.
-
(2015)
Biomedres Int
, pp. 2015
-
-
Mozos, I.1
Marginean, O.2
-
92
-
-
84897969679
-
Vitamin D and risk of cause specific death: Systematic review and meta-analysis of observational cohort and randomized intervention studies
-
Chowdhury R, Kunutsor S, Vitezova A, et al. Vitamin D and risk of cause specific death: systematic review and meta-analysis of observational cohort and randomized intervention studies. BMJ 2014; 348: g1903.
-
(2014)
BMJ
, vol.g1903
, pp. 348
-
-
Chowdhury, R.1
Kunutsor, S.2
Vitezova, A.3
-
93
-
-
79952021197
-
STATIN-D study: Comparison of the influences of rosuvastatin and fluvastatin treatment on the levels of 25 hydroxy vitamin D
-
Ertugrul DT, Yavuz B, Cil H, et al. STATIN-D study: comparison of the influences of rosuvastatin and fluvastatin treatment on the levels of 25 hydroxy vitamin D. CardiovascTher 2011; 29: 146-52.
-
(2011)
Cardiovascther
, vol.29
, pp. 146-152
-
-
Ertugrul, D.T.1
Yavuz, B.2
Cil, H.3
-
94
-
-
84879234697
-
Effect of simvastatin/ ezetimibe 10/10 mg versus simvastatin 40 mg on serumvitamin D levels
-
Liberopoulos EN, Makariou SE, Moutzouri E, et al. Effect of simvastatin/ ezetimibe 10/10 mg versus simvastatin 40 mg on serumvitamin D levels. J CardiovascPharmacolTher 2013; 18: 229-33.
-
(2013)
J Cardiovascpharmacolther
, vol.18
, pp. 229-233
-
-
Liberopoulos, E.N.1
Makariou, S.E.2
Moutzouri, E.3
-
95
-
-
33947608004
-
Effects of Atorvastatin on vitamin D levels in patients with acute ischemic heart disease
-
Pérez-Castrillón JL, Vega G, Abad L, et al. Effects of Atorvastatin on vitamin D levels in patients with acute ischemic heart disease. Am J Cardiol 2007; 99: 903-5.
-
(2007)
Am J Cardiol
, vol.99
, pp. 903-905
-
-
Pérez-Castrillón, J.L.1
Vega, G.2
Abad, L.3
-
96
-
-
84906708202
-
Comparative Effect of Atorvastatin and Rosuvastatin on 25-hydroxy-Vitamin D Levels in Non-diabetic Patients with Dyslipidaemia: A Prospective Randomized Open-label Pilot Study
-
Anagnostis P, Adamidou F, Slavakis A, et al. Comparative Effect of Atorvastatin and Rosuvastatin on 25-hydroxy-Vitamin D Levels in Non-diabetic Patients with Dyslipidaemia: A Prospective Randomized Open-label Pilot Study. Open Cardiovasc Med J 2014; 8: 55-60.
-
(2014)
Open Cardiovasc Med J
, vol.8
, pp. 55-60
-
-
Anagnostis, P.1
Adamidou, F.2
Slavakis, A.3
-
97
-
-
77954768612
-
Simvastatin does not affect vitamin d status, but low vitamin d levels are associated with dyslipidemia: Results from a randomised, controlled trial
-
Rejnmark L, Vestergaard P, Heickendorff L, Mosekilde L. Simvastatin does not affect vitamin d status, but low vitamin d levels are associated with dyslipidemia: results from a randomised, controlled trial. Int J Endocrinol 2010; 2010: 957174.
-
(2010)
Int J Endocrinol
, vol.2010
-
-
Rejnmark, L.1
Vestergaard, P.2
Heickendorff, L.3
Mosekilde, L.4
-
98
-
-
84938084844
-
Lipidand Blood Pressure Meta-analysis Collaboration (LBPMC) Group. Statin therapy and plasma coenzyme Q10 concentrations-A systematic review and meta-analysis of placebo-controlled trials
-
Banach M, Serban C, Ursoniu S, et al.; Lipidand Blood Pressure Meta-analysis Collaboration (LBPMC) Group. Statin therapy and plasma coenzyme Q10 concentrations-A systematic review and meta-analysis of placebo-controlled trials. Pharmacol Res 2015; 99: 329-36.
-
(2015)
Pharmacol Res
, vol.99
, pp. 329-336
-
-
Banach, M.1
Serban, C.2
Ursoniu, S.3
-
99
-
-
42349116146
-
Comparison of effects of pitavastatin and atorvastatin on plasma coenzyme Q10 in heterozygous familial hypercholesterolemia: Results from a crossover study
-
Kawashiri MA, Nohara A, Tada H, et al. Comparison of effects of pitavastatin and atorvastatin on plasma coenzyme Q10 in heterozygous familial hypercholesterolemia: results from a crossover study. ClinPharmacolTher 2008; 83: 731-9.
-
(2008)
Clinpharmacolther
, vol.83
, pp. 731-739
-
-
Kawashiri, M.A.1
Nohara, A.2
Tada, H.3
-
100
-
-
84908667304
-
Coenzyme Q10 supplementation decreases statin-related mild-to-moderate muscle symptoms: Arandomized clinical study
-
Skarlovnik A, Jani_ M, Lunder M, et al. Coenzyme Q10 supplementation decreases statin-related mild-to-moderate muscle symptoms: arandomized clinical study. Med SciMonit 2014; 20: 2183-8.
-
(2014)
Med Scimonit
, vol.20
, pp. 2183-2188
-
-
Skarlovnik, A.1
Jani, M.2
Lunder, M.3
-
101
-
-
84919935151
-
A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy
-
Taylor BA, Lorson L, White CM, Thompson PD. A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy. Atherosclerosis. 2015; 238: 329-35.
-
(2015)
Atherosclerosis
, vol.238
, pp. 329-335
-
-
Taylor, B.A.1
Lorson, L.2
White, C.M.3
Thompson, P.D.4
-
102
-
-
84920471176
-
Lipid and BloodPressure Meta-analysis Collaboration Group. Effects of coenzyme Q10 on statin-induced myopathy: A meta-analysis of randomized controlled trials
-
Banach M, Serban C, Sahebkar A, et al.; Lipid and BloodPressure Meta-analysis Collaboration Group. Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials. Mayo Clin Proc 2015; 90: 24-34.
-
(2015)
Mayo Clin Proc
, vol.90
, pp. 24-34
-
-
Banach, M.1
Serban, C.2
Sahebkar, A.3
-
103
-
-
84928027364
-
Nutraceuticals in lipid-lowering treatment: A narrative review on the role of chitosan
-
Patti AM, Katsiki N, Nikolic D, Al-Rasadi K, Rizzo M. Nutraceuticals in lipid-lowering treatment: a narrative review on the role of chitosan. Angiology 2015; 66: 416-21.
-
(2015)
Angiology
, vol.66
, pp. 416-421
-
-
Patti, A.M.1
Katsiki, N.2
Nikolic, D.3
Al-Rasadi, K.4
Rizzo, M.5
-
104
-
-
84971298472
-
A systematic review and meta-analysis of the impact of Spirulina supplementation on plasma lipid concentrations
-
[Epub ahead of print]
-
Serban MC, Sahebkar A, Dragan S, et al. A systematic review and meta-analysis of the impact of Spirulina supplementation on plasma lipid concentrations. ClinNutr 2015 [Epub ahead of print]
-
(2015)
Clinnutr
-
-
Serban, M.C.1
Sahebkar, A.2
Dragan, S.3
-
105
-
-
84928392457
-
Banach M.Lipid profile and glucose changes after supplementation with astaxanthin: A systematic review and meta-analysis of randomized controlled trials
-
Ursoniu S, Sahebkar A, Serban MC, Banach M.Lipid profile and glucose changes after supplementation with astaxanthin: a systematic review and meta-analysis of randomized controlled trials. Arch Med Sci 2015; 11: 253-66.
-
(2015)
Arch Med Sci
, vol.11
, pp. 253-266
-
-
Ursoniu, S.1
Sahebkar, A.2
Serban, M.C.3
-
107
-
-
76849117367
-
Lipidlowering efficacy of red yeast rice in a population intolerant to statins
-
Venero CV, Venero JV, Wortham DC, Thompson PD. Lipidlowering efficacy of red yeast rice in a population intolerant to statins. Am J Cardiol 2010; 105: 664-6.
-
(2010)
Am J Cardiol
, vol.105
, pp. 664-666
-
-
Venero, C.V.1
Venero, J.V.2
Wortham, D.C.3
Thompson, P.D.4
-
108
-
-
73149101073
-
Tolerability of red yeast rice (2, 400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance
-
Halbert SC, French B, Gordon RY, et al. Tolerability of red yeast rice (2, 400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance. Am J Cardiol 2010; 105: 198-204.
-
(2010)
Am J Cardiol
, vol.105
, pp. 198-204
-
-
Halbert, S.C.1
French, B.2
Gordon, R.Y.3
-
109
-
-
36048987346
-
Effect of ezetimibe inpatients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin
-
Gazi IF, Daskalopoulou SS, Nair DR, Mikhailidis DP. Effect of ezetimibe inpatients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin. Curr Med Res Opin 2007; 23: 2183-92.
-
(2007)
Curr Med Res Opin
, vol.23
, pp. 2183-2192
-
-
Gazi, I.F.1
Daskalopoulou, S.S.2
Nair, D.R.3
Mikhailidis, D.P.4
-
110
-
-
0037504445
-
Ezetimibe Study Group. Effect of ezetimibeco administered with atorvastatin in 628 patients with primary hypercholesterolemia: A prospective, randomized, double-blind trial
-
Ballantyne CM, Houri J, Notarbartolo A, et al; Ezetimibe Study Group. Effect of ezetimibeco administered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003; 107: 2409-15.
-
(2003)
Circulation
, vol.107
, pp. 2409-2415
-
-
Ballantyne, C.M.1
Houri, J.2
Notarbartolo, A.3
-
111
-
-
79956099377
-
Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia: Systematic review and metaanalysis
-
Mikhailidis DP, Lawson RW, McCormick AL, et al. Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia: systematic review and metaanalysis. Curr Med Res Opin 2011; 27: 1191-210.
-
(2011)
Curr Med Res Opin
, vol.27
, pp. 1191-1210
-
-
Mikhailidis, D.P.1
Lawson, R.W.2
McCormick, A.L.3
-
112
-
-
84929329231
-
Simvastatin-ezetimibe combination therapy is associated with a lower rate of major adverse cardiac events in type 2 diabetics than high potency statins alone: A population-based dynamic cohort study
-
Chang SH, Wu LS, Lee CH, et al. Simvastatin-ezetimibe combination therapy is associated with a lower rate of major adverse cardiac events in type 2 diabetics than high potency statins alone: A population-based dynamic cohort study. Int J Cardiol 2015; 190: 20-5.
-
(2015)
Int J Cardiol
, vol.190
, pp. 20-25
-
-
Chang, S.H.1
Wu, L.S.2
Lee, C.H.3
-
116
-
-
84876724789
-
Effects of ezetimibe on atherogenic lipoproteins and glucose metabolism in patients with diabetes and glucose intolerance
-
Tsunoda T, Nozue T, Yamada M, et al. Effects of ezetimibe on atherogenic lipoproteins and glucose metabolism in patients with diabetes and glucose intolerance. Diabetes Res ClinPract 2013; 100: 46-52.
-
(2013)
Diabetes Res Clinpract
, vol.100
, pp. 46-52
-
-
Tsunoda, T.1
Nozue, T.2
Yamada, M.3
-
117
-
-
84931411520
-
IMPROVE-IT Investigators. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
-
** The first study to report significant reductions in CVD risk with ezetimibe/simvastatin therapy in very high-risk patients achieving even lower LDL-C levels compared with simvastatin monotherapy
-
Cannon CP, Blazing MA, Giugliano RP, et al.; IMPROVE-IT Investigators. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med 2015; 372: 2387-97. ** The first study to report significant reductions in CVD risk with ezetimibe/simvastatin therapy in very high-risk patients achieving even lower LDL-C levels compared with simvastatin monotherapy
-
(2015)
N Engl J Med
, vol.372
, pp. 2387-2397
-
-
Cannon, C.P.1
Blazing, M.A.2
Giugliano, R.P.3
-
118
-
-
84953425720
-
Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity CReactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT
-
Bohula EA, Giugliano RP, Cannon CP, et al. Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity CReactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT. Circulation 2015; 132: 1224-33.
-
(2015)
Circulation
, vol.132
, pp. 1224-1233
-
-
Bohula, E.A.1
Giugliano, R.P.2
Cannon, C.P.3
-
119
-
-
84964013895
-
Clinical implications of the IMPROVE-ITtrial in the light of current and future lipidlowering treatment options
-
Nov 11. [Epub ahead of print]
-
Serban MC, Banach M, Mikhailidis DP. Clinical implications of the IMPROVE-ITtrial in the light of current and future lipidlowering treatment options. ExpertOpin Pharmacother 2015 Nov 11. [Epub ahead of print]
-
(2015)
Expertopin Pharmacother
-
-
Serban, M.C.1
Banach, M.2
Mikhailidis, D.P.3
-
120
-
-
59449103939
-
Cost effectiveness of ezetimibe in patients with cardiovascular disease and statin intolerance or contraindications: A Markovmodel
-
Ara R, Pandor A, Tumur I, et al. Cost effectiveness of ezetimibe in patients with cardiovascular disease and statin intolerance or contraindications: a Markovmodel. Am J Cardiovasc Drugs 2008; 8: 419-27.
-
(2008)
Am J Cardiovasc Drugs
, vol.8
, pp. 419-427
-
-
Ara, R.1
Pandor, A.2
Tumur, I.3
-
121
-
-
84886854727
-
Incremental lowering of low-density lipoprotein cholesterol with ezetimibe 20 mg vs 10 mg daily in patients receiving concomitant statin therapy
-
Ziada A, Schwarz UI, DeGorter MK, et al. Incremental lowering of low-density lipoprotein cholesterol with ezetimibe 20 mg vs 10 mg daily in patients receiving concomitant statin therapy. Can J Cardiol2013; 29: 1395-9.
-
Can J Cardiol2013
, vol.29
, pp. 1395-1399
-
-
Ziada, A.1
Schwarz, U.I.2
Degorter, M.K.3
-
122
-
-
84874292234
-
Adverse events following statin-fenofibrate therapy versus statin alone: A meta-analysis of randomized controlled trials
-
Geng Q, Ren J, Chen H, Lee C, Liang W. Adverse events following statin-fenofibrate therapy versus statin alone: a meta-analysis of randomized controlled trials. ClinExpPharmacolPhysiol 2013; 40: 219-26.
-
(2013)
Clinexppharmacolphysiol
, vol.40
, pp. 219-226
-
-
Geng, Q.1
Ren, J.2
Chen, H.3
Lee, C.4
Liang, W.5
-
123
-
-
84873689744
-
Adverse events of statinfenofibric acid versus statin mono therapy: A meta-analysis of randomized controlled trials
-
Geng Q, Ren J, Chen H, Lee C, Liang W. Adverse events of statinfenofibric acid versus statin mono therapy: a meta-analysis of randomized controlled trials. Curr Med Res Opin 2013; 29: 181-8.
-
(2013)
Curr Med Res Opin
, vol.29
, pp. 181-188
-
-
Geng, Q.1
Ren, J.2
Chen, H.3
Lee, C.4
Liang, W.5
-
124
-
-
84856219904
-
Evaluation of the incidence and risk factors for development of fenofibrate-associated nephrotoxicity
-
Attridge RL, Linn WD, Ryan L, et al. Evaluation of the incidence and risk factors for development of fenofibrate-associated nephrotoxicity. J ClinLipidol 2012; 6: 19-26.
-
(2012)
J Clinlipidol
, vol.6
, pp. 19-26
-
-
Attridge, R.L.1
Linn, W.D.2
Ryan, L.3
-
125
-
-
11144239674
-
Reporting rate of rhabdomyolysis with fenofibrate +statin versus gemfibrozil + any statin
-
Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate +statin versus gemfibrozil + any statin. Am J Cardiol 2005; 95: 120-2.
-
(2005)
Am J Cardiol
, vol.95
, pp. 120-122
-
-
Jones, P.H.1
Davidson, M.H.2
-
126
-
-
84955676391
-
Systematic literature review and meta-analysis of dual therapy with fenofibrate or fenofibric acid and a statin versus a double or equivalent dose of statin monotherapy
-
Ouwens MJ, Nauta J, Ansquer JC, Driessen S. Systematic literature review and meta-analysis of dual therapy with fenofibrate or fenofibric acid and a statin versus a double or equivalent dose of statin monotherapy. Curr Med Res Opin 2015: 1-13.
-
(2015)
Curr Med Res Opin
, pp. 1-13
-
-
Ouwens, M.J.1
Nauta, J.2
Ansquer, J.C.3
Driessen, S.4
-
127
-
-
80053185929
-
Fenofibrate: A review of its use in dyslipidaemia
-
McKeage K, Keating GM. Fenofibrate: a review of its use in dyslipidaemia. Drugs 2011; 71: 1917-46.
-
(2011)
Drugs
, vol.71
, pp. 1917-1946
-
-
McKeage, K.1
Keating, G.M.2
-
128
-
-
64749095070
-
Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators. Effects of fenofibrate treatment on cardiovascular disease risk in 9, 795 individuals with type 2 diabetes and various components of the metabolic syndrome: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
-
Scott R, O'Brien R, Fulcher G, et al; Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators. Effects of fenofibrate treatment on cardiovascular disease risk in 9, 795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care 2009; 32: 493-8.
-
(2009)
Diabetes Care
, vol.32
, pp. 493-498
-
-
Scott, R.1
O'brien, R.2
Fulcher, G.3
-
129
-
-
77951704587
-
Effects of combination lipid therapy in type 2 diabetes mellitus
-
ACCORD Study Group
-
ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1563-74.
-
(2010)
N Engl J Med
, vol.362
, pp. 1563-1574
-
-
Ginsberg, H.N.1
Elam, M.B.2
Lovato, L.C.3
-
130
-
-
80053173357
-
Short-term effect of fenofibrate on C-reactive protein: A meta-analysis of randomized control ledtrials
-
Ye J, Kiage JN, Arnett DK, et al. Short-term effect of fenofibrate on C-reactive protein: A meta-analysis of randomized control ledtrials. DiabetolMetabSyndr 2011; 3: 24.
-
(2011)
Diabetolmetabsyndr
, vol.3
, pp. 24
-
-
Ye, J.1
Kiage, J.N.2
Arnett, D.K.3
-
132
-
-
84895775124
-
Bile acid sequestrants: Glucoselowering mechanisms and efficacy in type 2 diabetes
-
Hansen M, Sonne DP, Knop FK. Bile acid sequestrants: glucoselowering mechanisms and efficacy in type 2 diabetes. Curr Diab Rep 2014; 14: 482.
-
(2014)
Curr Diab Rep
, vol.14
, pp. 482
-
-
Hansen, M.1
Sonne, D.P.2
Knop, F.K.3
-
133
-
-
84940021344
-
CARDIoGRAMplusC4D Consortium, Stewart AF, Samani NJ, Roberts R, Paré G. Effect of Bile Acid Sequestrants on the Risk of Cardiovascular Events: A Mendelian Randomization Analysis
-
Ross S, D'Mello M, Anand S, Eikelboom J; CARDIoGRAMplusC4D Consortium, Stewart AF, Samani NJ, Roberts R, Paré G. Effect of Bile Acid Sequestrants on the Risk of Cardiovascular Events: A Mendelian Randomization Analysis. CircCardiovasc Genet 2015; 8: 618-27.
-
(2015)
Circcardiovasc Genet
, vol.8
, pp. 618-627
-
-
Ross, S.1
D'mello, M.2
Anand, S.3
Eikelboom, J.4
-
134
-
-
33645098531
-
Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: A scientific review
-
Insull W Jr. Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review. South Med J 2006; 99: 257-73.
-
(2006)
South Med J
, vol.99
, pp. 257-273
-
-
Insull, W.1
-
135
-
-
33947124605
-
Safety considerations with gastro intestinally active lipid-lowering drugs
-
Jacobson TA, Armani A, McKenney JM, Guyton JR. Safety considerations with gastro intestinally active lipid-lowering drugs. Am J Cardiol 2007; 99: 47C-55C.
-
(2007)
Am J Cardiol
, vol.99
, pp. 47C-55C
-
-
Jacobson, T.A.1
Armani, A.2
McKenney, J.M.3
Guyton, J.R.4
-
136
-
-
33645735636
-
Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and highsensitivity C-reactive protein when added to statins in patients with hypercholesterolemia
-
Bays HE, Davidson M, Jones MR, Abby SL. Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and highsensitivity C-reactive protein when added to statins in patients with hypercholesterolemia. Am J Cardiol 2006; 97: 1198-205.
-
(2006)
Am J Cardiol
, vol.97
, pp. 1198-1205
-
-
Bays, H.E.1
Davidson, M.2
Jones, M.R.3
Abby, S.L.4
-
137
-
-
41949100903
-
Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia
-
Paolini JF, Mitchel YB, Reyes R, et al. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am J Cardiol 2008; 101: 625-30.
-
(2008)
Am J Cardiol
, vol.101
, pp. 625-630
-
-
Paolini, J.F.1
Mitchel, Y.B.2
Reyes, R.3
-
138
-
-
53149118030
-
Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia
-
Maccubbin D, Bays HE, Olsson AG, et al. Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Int J ClinPract 2008; 62: 1959-70.
-
(2008)
Int J Clinpract
, vol.62
, pp. 1959-1970
-
-
Maccubbin, D.1
Bays, H.E.2
Olsson, A.G.3
-
139
-
-
84898899088
-
Effects of niacin combination therapy with statin or bile acid resin on lipoproteins and cardiovascular disease
-
Zambon A, Zhao XQ, Brown BG, Brunzell JD. Effects of niacin combination therapy with statin or bile acid resin on lipoproteins and cardiovascular disease. Am J Cardiol 2014; 113: 1494-8.
-
(2014)
Am J Cardiol
, vol.113
, pp. 1494-1498
-
-
Zambon, A.1
Zhao, X.Q.2
Brown, B.G.3
Brunzell, J.D.4
-
141
-
-
79959919684
-
Pleiotropic effects of nicotinic acid: Beyond high density lipoprotein cholesterol elevation
-
Florentin M, Liberopoulos EN, Kei A, et al. Pleiotropic effects of nicotinic acid: beyond high density lipoprotein cholesterol elevation. Curr VascPharmacol 2011; 9: 385-400.
-
(2011)
Curr Vascpharmacol
, vol.9
, pp. 385-400
-
-
Florentin, M.1
Liberopoulos, E.N.2
Kei, A.3
-
142
-
-
84855171302
-
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy
-
AIM-HIGH Investigators, Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365: 2255-67.
-
(2011)
N Engl J Med
, vol.365
, pp. 2255-2267
-
-
Investigators, A.-H.1
Boden, W.E.2
Probstfield, J.L.3
Anderson, T.4
-
143
-
-
84877299845
-
HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/ laropiprant: Trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment
-
HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/ laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013; 34: 1279-91.
-
(2013)
Eur Heart J
, vol.34
, pp. 1279-1291
-
-
-
145
-
-
84925259873
-
Systematic review of CETP inhibitors for increasing high-density lipoprotein cholesterol: Where do these agents stand in the approval process?
-
Bishop BM. Systematic review of CETP inhibitors for increasing high-density lipoprotein cholesterol: where do these agents stand in the approval process? Am J Ther 2015; 22: 147-58.
-
(2015)
Am J Ther
, vol.22
, pp. 147-158
-
-
Bishop, B.M.1
-
147
-
-
36348975228
-
ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events
-
Barter PJ, Caulfield M, Eriksson M, et al; ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357: 2109-22.
-
(2007)
N Engl J Med
, vol.357
, pp. 2109-2122
-
-
Barter, P.J.1
Caulfield, M.2
Eriksson, M.3
-
148
-
-
84906096364
-
Highdensity lipoprotein, vascular risk, cancer and infection: A case of quantity and quality?
-
Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Highdensity lipoprotein, vascular risk, cancer and infection: a case of quantity and quality? Curr Med Chem 2014; 21: 2917-26.
-
(2014)
Curr Med Chem
, vol.21
, pp. 2917-2926
-
-
Katsiki, N.1
Athyros, V.G.2
Karagiannis, A.3
Mikhailidis, D.P.4
-
149
-
-
84861585543
-
Dysfunctional HDL: A novel important diagnostic and therapeutic target in cardiovascular disease?
-
Otocka-Kmiecik A, Mikhailidis DP, Nicholls SJ, et al. Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease? Prog Lipid Res 2012; 51: 314-24.
-
(2012)
Prog Lipid Res
, vol.51
, pp. 314-324
-
-
Otocka-Kmiecik, A.1
Mikhailidis, D.P.2
Nicholls, S.J.3
-
150
-
-
78549235583
-
Determining the Efficacy and Tolerability Investigators. Safety of anacetrapib in patients with or at high risk for coronary heart disease
-
Cannon CP, Shah S, Dansky HM, et al; Determining the Efficacy and Tolerability Investigators. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010; 363: 2406-15.
-
(2010)
N Engl J Med
, vol.363
, pp. 2406-2415
-
-
Cannon, C.P.1
Shah, S.2
Dansky, H.M.3
-
151
-
-
58649091088
-
Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients
-
Bloomfield D, Carlson GL, Sapre A, et al. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am Heart J 2009; 157: 352-360.e2.
-
Am Heart J
, vol.352-360
-
-
Bloomfield, D.1
Carlson, G.L.2
Sapre, A.3
-
152
-
-
84870045994
-
Effects of dalcetrapib in patients with a recent acute coronary syndrome
-
Schwartz GG, Olsson AG, Abt M, et al; dal-OUTCOMES Investigators. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012; 367: 2089-99.
-
(2012)
N Engl J Med
, vol.367
, pp. 2089-2099
-
-
Schwartz, G.G.1
Olsson, A.G.2
-
153
-
-
84938748425
-
Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): A randomised, double-blind, placebocontrolled phase 2 trial
-
Hovingh GK, Kastelein JJ, van Deventer SJ, et al. Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebocontrolled phase 2 trial. Lancet 2015; 386: 452-60.
-
(2015)
Lancet
, vol.386
, pp. 452-460
-
-
Hovingh, G.K.1
Kastelein, J.J.2
Van Deventer, S.J.3
-
154
-
-
84871975694
-
PCSK9 inhibition-a novel mechanism to treat lipid disorders?
-
Banach M, Rizzo M, Obradovic M, et al. PCSK9 inhibition-a novel mechanism to treat lipid disorders? Curr Pharm Des 2013; 19: 3869-77.
-
(2013)
Curr Pharm Des
, vol.19
, pp. 3869-3877
-
-
Banach, M.1
Rizzo, M.2
Obradovic, M.3
-
155
-
-
84941993216
-
PCSK9 inhibitors-past, present and future
-
Reiner _
-
Reiner _. PCSK9 inhibitors-past, present and future. Expert Opin Drug MetabToxicol 2015; 11: 1517-21.
-
(2015)
Expert Opin Drug Metabtoxicol
, vol.11
, pp. 1517-1521
-
-
-
156
-
-
84942104125
-
PCSK9 (Proprotein convertase subtilisin/ kexin type 9) inhibitors: Past, present, and the future
-
Shimada YJ, Cannon CP. PCSK9 (Proprotein convertase subtilisin/ kexin type 9) inhibitors: past, present, and the future. Eur Heart J 2015; 36: 2415-24.
-
(2015)
Eur Heart J
, vol.36
, pp. 2415-2424
-
-
Shimada, Y.J.1
Cannon, C.P.2
-
157
-
-
84893648929
-
Athyros VG. Dyslipidaemia in 2013: New statin guidelines and promising novel therapeutics
-
Mikhailidis DP, Athyros VG. Dyslipidaemia in 2013: New statin guidelines and promising novel therapeutics. Nat Rev Cardiol 2014; 11: 72-4.
-
(2014)
Nat Rev Cardiol
, vol.11
, pp. 72-74
-
-
Mikhailidis, D.P.1
-
158
-
-
85018197350
-
Efficiency and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibody on hypercholesterolemia: A meta-analysis of 20 randomized controlled trials
-
Li C, Lin L, Zhang W, et al. Efficiency and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibody on hypercholesterolemia: a meta-analysis of 20 randomized controlled trials. J Am Heart Assoc 2015; 4: e001937.
-
(2015)
J am Heart Assoc
, vol.4
-
-
Li, C.1
Lin, L.2
Zhang, W.3
-
159
-
-
84902157271
-
GAUSS-2 Investigators. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: The GAUSS-2 randomized, placebocontrolled phase 3 clinical trial of evolocumab
-
Stroes E, Colquhoun D, Sullivan D, et al.; GAUSS-2 Investigators. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebocontrolled phase 3 clinical trial of evolocumab. J Am CollCardiol 2014; 63: 2541-8.
-
(2014)
J am Collcardiol
, vol.63
, pp. 2541-2548
-
-
Stroes, E.1
Colquhoun, D.2
Sullivan, D.3
-
160
-
-
84947965019
-
ODYSSEY ALTERNATIVE Investigators. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial
-
Moriarty PM, Thompson PD, Cannon CP, et al.; ODYSSEY ALTERNATIVE Investigators. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial. J Clin-Lipidol 2015; 9: 758-69.
-
(2015)
J Clin-Lipidol
, vol.9
, pp. 758-769
-
-
Moriarty, P.M.1
Thompson, P.D.2
Cannon, C.P.3
-
161
-
-
84983160332
-
Langslet G, et al.ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia
-
Kastelein JJ, Ginsberg HN, Langslet G, et al.ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J 2015; 36: 2996-3003.
-
(2015)
Eur Heart J
, vol.36
, pp. 2996-3003
-
-
Kastelein, J.J.1
Ginsberg, H.N.2
-
162
-
-
84921459685
-
TESLA Investigators. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): A randomised, double-blind, placebo-controlled trial
-
Raal FJ, Honarpour N, Blom DJ, et al.; TESLA Investigators. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet 2015; 385 (9965): 341-50.
-
(2015)
Lancet
, vol.385
, Issue.9965
, pp. 341-350
-
-
Raal, F.J.1
Honarpour, N.2
Blom, D.J.3
-
163
-
-
84921483643
-
RUTHERFORD-2 Investigators. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): A randomised, double-blind, placebo-controlled trial
-
Raal FJ, Stein EA, Dufour R, et al.; RUTHERFORD-2 Investigators. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet 2015; 385 (9965): 331-40.
-
(2015)
Lancet
, vol.385
, Issue.9965
, pp. 331-340
-
-
Raal, F.J.1
Stein, E.A.2
Dufour, R.3
-
164
-
-
84878388937
-
The next generation of novel lowdensity lipoprotein cholesterol-lowering agents: Proprotein convertase subtilisin/kexin 9 inhibitors
-
Shen L, Peng H, Xu D, Zhao S. The next generation of novel lowdensity lipoprotein cholesterol-lowering agents: proprotein convertase subtilisin/kexin 9 inhibitors. Pharmacol Res 2013; 73: 27-34.
-
(2013)
Pharmacol Res
, vol.73
, pp. 27-34
-
-
Shen, L.1
Peng, H.2
Xu, D.3
Zhao, S.4
-
165
-
-
84958604041
-
The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: A network meta-analysis
-
Nov 17. pii: ehv563. [Epub ahead of print]
-
Lipinski MJ, Benedetto U, Escarcega RO, et al. The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis. Eur Heart J 2015 Nov 17. pii: ehv563. [Epub ahead of print]
-
(2015)
Eur Heart J
-
-
Lipinski, M.J.1
Benedetto, U.2
Escarcega, R.O.3
-
166
-
-
84926206074
-
Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events
-
**The first study to report significant reductions in CVD risk following evolocumab therapy
-
Sabatine MS, Giugliano RP, Wiviott SD, et al; Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1500-9. **The first study to report significant reductions in CVD risk following evolocumab therapy
-
(2015)
N Engl J Med
, vol.372
, pp. 1500-1509
-
-
Sabatine, M.S.1
Giugliano, R.P.2
Wiviott, S.D.3
-
167
-
-
84926191670
-
ODYSSEY LONG TERM Investigators. Efficacy and safety ofalirocumab in reducing lipids and cardiovascular events
-
**The first study to report significant reductions in CVD risk following alirocumab therapy
-
Robinson JG, Farnier M, Krempf M, et al; ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1489-99. **The first study to report significant reductions in CVD risk following alirocumab therapy
-
(2015)
N Engl J Med
, vol.372
, pp. 1489-1499
-
-
Robinson, J.G.1
Farnier, M.2
Krempf, M.3
-
168
-
-
84940106915
-
New developments in atherosclerosis: Clinical potential of PCSK9 inhibition
-
Giunzioni I, Tavori H. New developments in atherosclerosis: clinical potential of PCSK9 inhibition. Vasc Health Risk Manag 2015; 11: 493-501.
-
(2015)
Vasc Health Risk Manag
, vol.11
, pp. 493-501
-
-
Giunzioni, I.1
Tavori, H.2
-
169
-
-
84995673240
-
Defining the Role of PCSK9 Inhibitors in the Treatment of Hyperlipidemia
-
Nov 23. [Epub ahead of print]
-
Whayne TF Jr. Defining the Role of PCSK9 Inhibitors in the Treatment of Hyperlipidemia. Am J Cardiovasc Drugs. 2015 Nov 23. [Epub ahead of print]
-
(2015)
Am J Cardiovasc Drugs
-
-
Whayne, T.F.1
-
170
-
-
84902293165
-
Hypolipidaemic drug treatment: Yesterday is not gone yet, today is challenging and tomorrow is comingsoon; let us combine them all
-
Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. Hypolipidaemic drug treatment: yesterday is not gone yet, today is challenging and tomorrow is comingsoon; let us combine them all. Curr Pharm Des 2014; 20: 6350-7.
-
(2014)
Curr Pharm Des
, vol.20
, pp. 6350-6357
-
-
Athyros, V.G.1
Tziomalos, K.2
Karagiannis, A.3
Mikhailidis, D.P.4
-
171
-
-
84895548648
-
Lomitapide and mipomersen: Two first-inclass drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia
-
Rader DJ, Kastelein JJ. Lomitapide and mipomersen: two first-inclass drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia. Circulation. 2014; 129: 1022-32.
-
(2014)
Circulation
, vol.129
, pp. 1022-1032
-
-
Rader, D.J.1
Kastelein, J.J.2
-
172
-
-
84949870464
-
Is Targeting microRNAs the Philosopher's Stone for Vascular Disease?
-
Athyros VG, Katsiki N, Karagiannis A. Is Targeting microRNAs the Philosopher's Stone for Vascular Disease? Curr Vasc Pharmacol 2016; 14: 88-97.
-
(2016)
Curr Vasc Pharmacol
, vol.14
, pp. 88-97
-
-
Athyros, V.G.1
Katsiki, N.2
Karagiannis, A.3
-
173
-
-
84937128430
-
Editorial: MicroRNAs: Potential Targets for the Treatment of Cardiovascular Disease
-
Athyros VG, Katsiki N, Karagiannis A. Editorial: microRNAs: Potential Targets for the Treatment of Cardiovascular Disease. Curr VascPharmacol 2015; 13: 366-7.
-
(2015)
Curr Vascpharmacol
, vol.13
, pp. 366-367
-
-
Athyros, V.G.1
Katsiki, N.2
Karagiannis, A.3
-
174
-
-
84875210174
-
Therapeutic gene targeting approaches for the treatment of dyslipidemias and atherosclerosis
-
Mäkinen PI, Ylä-Herttuala S. Therapeutic gene targeting approaches for the treatment of dyslipidemias and atherosclerosis. Curr Opin Lipidol 2013; 24: 116-22.
-
(2013)
Curr Opin Lipidol
, vol.24
, pp. 116-122
-
-
Mäkinen, P.I.1
Ylä-Herttuala, S.2
|